11-16-2022 Media Only News Briefing: Risk to quit with Dr. J. Taylor Hays, Mayo Clinic Nicotine Dependence Center
Cigarette smoking remains the leading cause of preventable disease, disability and death in the U.S., accounting for more than 480,000 deaths every year, according to the Centers for Disease Control and Prevention. Lung cancer claims more lives each year than colon, breast and prostate cancers combined. Although the disease can occur in people who have never smoked, people who smoke or have smoked have the greatest risk of lung cancer, as well as other cancers. The American Cancer… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 16, 2022 Category: Databases & Libraries Source Type: news
CRISPR For Cancer Takes a Big Step Forward
Researchers have made an important step forward toward a long-desired goal: using the gene-editing technology CRISPR to treat cancer.
In a study published in Nature, scientists recruited 16 people who had already received standard treatment for their cancer (which included colon, head and neck, lung, skin, and more) but whose cancers had returned. They wanted to use the gene-editing therapy in a new way and infuse patients with an army of immune cells that had been genetically modified to specifically fight their individual cancers.
Scientists genetically sequenced each patient’s blood cells and tumors in order to ...
Source: TIME: Health - November 10, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer COVID-19 healthscienceclimate Source Type: news
How a Wrong Diagnosis Masked a Young Woman's Cancer
A young woman with Lynch syndrome talks about her long journey to finally receiving a colon cancer diagnosis. (Source: WebMD Health)
Source: WebMD Health - November 8, 2022 Category: Consumer Health News Source Type: news
Top Medical Groups, Hospitals Urge Better Access to Lung Cancer Screening
WEDNESDAY, Nov. 2, 2022 -- Screening tests routinely catch cases of breast and colon cancer early, but a screening test for lung cancer is sorely underused in high-risk people and that needs to change, more than 50 cancer organizations said in a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 2, 2022 Category: Pharmaceuticals Source Type: news
Top Medical Groups, Hospitals Urge Better Access to Lung Cancer Screening
WEDNESDAY, Nov. 2, 2022 -- Screening tests routinely catch cases of breast and colon cancer early, but a screening test for lung cancer is sorely underused in high-risk people and that needs to change, more than 50 cancer organizations said in a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 2, 2022 Category: General Medicine Source Type: news
Mayo Clinic Minute: Understanding lung cancer
November is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than colon, breast and prostate cancers combined, according to the American Cancer Society. Watch: The Mayo Clinic Minute https://youtu.be/x1BvjsLly8k Journalists: Broadcast-quality video (1:14) is in the downloads at the end of this post. Please courtesy: "Mayo Clinic News Network." Read the script. Lung cancer is the second most common cancer in… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 2, 2022 Category: Databases & Libraries Source Type: news
What Causes Anal Itching?
Discussion
Pinworms are caused by the parasite Enterobius vermicularis. Humans are the only known reservoir and are infected by fecal-oral transmission of eggs or indirectly such as through contaminated clothing or bedding. It is commonly seen in children and can easily pass to family members, plus people can become easily reinfected. The incubation period is usually 1-2 months and eggs can survive outside humans for 2-3 weeks. Adult worms migrate at night from the anus to the perianal skin and vulvar areas causing anal or vulvar itching. The itching can cause sleep problems and scratching can cause secondary bacterial inf...
Source: PediatricEducation.org - October 31, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
EHR Time Improves Quality; Low-Cost Colon Cancer Screening; Tumors From 3D Printers
(MedPage Today) -- A study of 291 primary care physicians showed that devoting more time to electronic health records (EHRs) was associated with improvements in several quality indicators, including breast cancer screening. (Brigham and Women's... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 21, 2022 Category: Hematology Source Type: news
Fast food fever: how ultra-processed meals are unhealthier than you think
UPFs form 50% of Britons ’ calorie intake – and vegans beware, this includes many plant-based meals. Now food scientists are learning more about what makes them so damagingFor a long time it has been known that diets dominated by ultra-processed food (UPF) are more likely to lead to obesity. But recent research suggests that high UPF consumption also increases the risk of cardiovascular disease, dementia and, according to a recent American study involving 50,000 health professionals, of developing colon cancer.On a more general note, last month a study inNature Reviews Clinical Oncology found that people born after 199...
Source: Guardian Unlimited Science - October 16, 2022 Category: Science Authors: Andrew Anthony Tags: Food science Health & wellbeing Veganism Nutrition Fast food Life and style Society Source Type: news
Cancer signs: Tenesmus is a 'common' sign that a tumour is growing inside the colon
Diagnostic challenges are a major cause of poor prognosis in cancer care, so keeping abreast of warning signs is crucial. (Source: Daily Express - Health)
Source: Daily Express - Health - October 14, 2022 Category: Consumer Health News Source Type: news
Colonoscopies save lives. Doctors push back against European study that casts doubt
Colon cancer specialists worry that results of a study published this week in the New England Journal of Medicine could be misconstrued, and keep patients from getting lifesaving cancer screening.(Image credit: lechatnoir/Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - October 13, 2022 Category: Consumer Health News Authors: Allison Aubrey Source Type: news
What to know about colonoscopy after study questions its effectiveness
A new European study on colonoscopies -- the largest of its kind -- has complicated results, and it's left some people wondering whether they should have the procedure to screen for colon cancer. (Source: CNN.com - Health)
Source: CNN.com - Health - October 11, 2022 Category: Consumer Health News Source Type: news
NEJM: Colon cancer screening reduces mortality rates
A study published October 7 in the New England Journal of Medicine (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 10, 2022 Category: Radiology Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
